January 30 | 2020 2cureX uppdaterar om klinisk studie med metastaserande kolorektalcancer: 75 % av planerade patienter har behandlats i enlighet med IndiTreat testet Read more
January 30 | 2020 Update on 2cureX’s clinical trial in metastatic colorectal cancer: 75% of the scheduled patients have been treated in accordance with the IndiTreat test Read more
January 6 | 2020 2cureX fortsätter sin IP-expansion genom att säkra ett patent på sitt IndiTreat-test i Australien Read more
January 6 | 2020 2cureX continues its IP expansion by securing a patent on its IndiTreat test in Australia Read more
December 13 | 2019 Hospitals and cancer care givers can now offer the IndiTreat test to their cancer patients. Read more
December 13 | 2019 Sjukhus och cancervårdgivare kan nu erbjuda IndiTreat-testet till sina cancerpatienter. Read more
December 13 | 2019 2cureX presenterar framsteg i analysutveckling för IndiTreat® i immuno-onkologi vid ESMO Immuno-Oncology Congress i Genève 11-14 december 2019. Read more
December 13 | 2019 2cureX presented progression in the IndiTreat® immuno-oncology assay development at the ESMO Immuno-Oncology Congress in Geneva 11-14 Dec. 2019. Read more
December 10 | 2019 2cureX lanserar IndiTreat.com som en viktig komponent i 2cureX förberedelser för produktlanseringen av IndiTreat® 2020 Read more
December 10 | 2019 2cureX launches IndiTreat.com as an important component of 2cureX’s preparation for the product launch of IndiTreat® in 2020 Read more
November 22 | 2019 CORRECTION: 2cureX publishes interim report for the third quarter of 2019 Read more
November 22 | 2019 RÄTTELSE: 2cureX offentliggör delårsrapport för det tredje kvartalet 2019 Read more
November 6 | 2019 2cureX continues its efforts to ensure a strong IP protection for its IndiTreat test in the United States Read more